Co­herus re­struc­tures, ax­es 51 staffers in wake of an FDA re­jec­tion of its knock­off of Am­gen’s Neu­las­ta

Just two weeks af­ter the FDA spurned Co­herus’ ap­pli­ca­tion to sell a knock­off of Am­gen’s Neu­las­ta, the biosim­i­lar mak­er has come back with a plan …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA